Pricing updated 2016-05-05. Prices are subject to change without notice.
Gö 6983 inhibits several isoforms of protein kinase C (PKC; IC50 = 7, 7, 6, 10, 60, and 20,000 nM for PKCα, PKCβ, PKCγ, PKCδ, PKCζ, and PKCμ, respectively).1 It provides cardioprotective effects in myocardial ischemia/reperfusion by attenuating contractile dysfunction.2,3
|Formulation||A crystalline solid|
WARNING - This product is not for human or veterinary use.
|Shipping||Room temperature in continental US; may vary elsewhere|
|Stability||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Separate multiple batch numbers with commas
1. Gschwendt, M., Dieterich, S., Rennecke, J., et al. Inhibition of protein kinase C .mu. by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett 392 77-80 (1996).
2. Peterman, E.E., Taormina, P.I., Harvey, M., et al. Gö 6983 exerts cardioprotective effects in myocardial ischemia/reperfusion. J Cardiovasc Pharmacol 43 645-656 (2004).
3. Young, L.H., Balin, B.J., and Weis, M.T. Gö 6983: A fast acting protein kinase C inhibitor that attenuates myocardial ischemia/reperfusion injury. Cardiovasc Drug Rev 23(3) 255-272 (2005).
We offer you the deep and diverse knowledge of more than 100 in-house scientists and the expertise that comes from more than three decades of designing and developing the tools to advance biomedical research.
Cayman is know as a partner to scientists worldwide, responding to your needs with services in: